CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, today announced topline results from its landmark Synuclein-One Study sponsored by the National Institutes of Health (NIH).
CND raised an additional $1 million in venture financing from Top Corner Capital
Company Focuses on Innovative Diagnosis and Treatment of Neurodegenerative Diseases
Agreement with Beth Israel Deaconess Medical Center Solidifies Important Technology for CND’s Syn-One Test® and Creates Opportunity for Future Innovations in the Field
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $4.2 million grant from the Arizona Governor’s Office to support the creation of the world’s first digital biosignatures laboratory focused on neurodegenerative disorders.
Collaboration Focuses on CND’s Groundbreaking Syn-One Test® that Aids in the Diagnosis of Parkinson’s Disease and Other Neurodegenerative Disorders
Grant Supports the Evaluation of CND’s Skin Biopsy Test to Identity Early Signs of Parkinson’s Disease and Other Neurodegenerative Disorders and Serve as an Effective Marker for Future Treatments
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
Will Advance the Company’s Technology Designed to Aid the Diagnosis of Parkinson’s Disease and Other Neurological Disorders
Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological disorders